Impax Laboratories, Inc. (NASDAQ: IPXL) Stock Competitors & Peer Comparison

Impax Laboratories, Inc. (NASDAQ: IPXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPXL stands at 0. In comparison, RPRX has a market cap of 25.2B. Regarding current trading prices, IPXL is priced at $18.30 on the NASDAQ, while RPRX trades at $56.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPXL currently has a P/E ratio of -10.11, whereas RPRX's P/E ratio is 10.81. In terms of profitability, IPXL's ROE is -1.16%, compared to RPRX's ROE of +0.11%. Regarding short-term risk, IPXL is more volatile compared to RPRX. This indicates higher risk in terms of short-term price fluctuations for IPXL.Check RPRX's competition here

Impax Laboratories, Inc. (NASDAQ: IPXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPXL stands at 0. In comparison, CORT has a market cap of 12B. Regarding current trading prices, IPXL is priced at $18.30 on the NASDAQ, while CORT trades at $110.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPXL currently has a P/E ratio of -10.11, whereas CORT's P/E ratio is 316.49. In terms of profitability, IPXL's ROE is -1.16%, compared to CORT's ROE of +0.08%. Regarding short-term risk, IPXL is more volatile compared to CORT. This indicates higher risk in terms of short-term price fluctuations for IPXL.Check CORT's competition here

Impax Laboratories, Inc. (NASDAQ: IPXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPXL stands at 0. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, IPXL is priced at $18.30 on the NASDAQ, while WBA trades at $11.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPXL currently has a P/E ratio of -10.11, whereas WBA's P/E ratio is -1.64. In terms of profitability, IPXL's ROE is -1.16%, compared to WBA's ROE of -0.42%. Regarding short-term risk, IPXL is more volatile compared to WBA. This indicates higher risk in terms of short-term price fluctuations for IPXL.Check WBA's competition here

Impax Laboratories, Inc. (NASDAQ: IPXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPXL stands at 0. In comparison, LQDA has a market cap of 8B. Regarding current trading prices, IPXL is priced at $18.30 on the NASDAQ, while LQDA trades at $90.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPXL currently has a P/E ratio of -10.11, whereas LQDA's P/E ratio is 644.43. In terms of profitability, IPXL's ROE is -1.16%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, IPXL is more volatile compared to LQDA. This indicates higher risk in terms of short-term price fluctuations for IPXL.Check LQDA's competition here

Impax Laboratories, Inc. (NASDAQ: IPXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPXL stands at 0. In comparison, KNSA has a market cap of 5.8B. Regarding current trading prices, IPXL is priced at $18.30 on the NASDAQ, while KNSA trades at $76.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPXL currently has a P/E ratio of -10.11, whereas KNSA's P/E ratio is 84.51. In terms of profitability, IPXL's ROE is -1.16%, compared to KNSA's ROE of +0.14%. Regarding short-term risk, IPXL is more volatile compared to KNSA. This indicates higher risk in terms of short-term price fluctuations for IPXL.Check KNSA's competition here

Impax Laboratories, Inc. (NASDAQ: IPXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPXL stands at 0. In comparison, TRLV has a market cap of 1.5B. Regarding current trading prices, IPXL is priced at $18.30 on the NASDAQ, while TRLV trades at $8.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPXL currently has a P/E ratio of -10.11, whereas TRLV's P/E ratio is -20.83. In terms of profitability, IPXL's ROE is -1.16%, compared to TRLV's ROE of -0.44%. Regarding short-term risk, IPXL is more volatile compared to TRLV. This indicates higher risk in terms of short-term price fluctuations for IPXL.Check TRLV's competition here

Impax Laboratories, Inc. (NASDAQ: IPXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPXL stands at 0. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, IPXL is priced at $18.30 on the NASDAQ, while HROWL trades at $25.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPXL currently has a P/E ratio of -10.11, whereas HROWL's P/E ratio is N/A. In terms of profitability, IPXL's ROE is -1.16%, compared to HROWL's ROE of -0.34%. Regarding short-term risk, IPXL is more volatile compared to HROWL. This indicates higher risk in terms of short-term price fluctuations for IPXL.Check HROWL's competition here

Impax Laboratories, Inc. (NASDAQ: IPXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPXL stands at 0. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, IPXL is priced at $18.30 on the NASDAQ, while HROWM trades at $26.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPXL currently has a P/E ratio of -10.11, whereas HROWM's P/E ratio is N/A. In terms of profitability, IPXL's ROE is -1.16%, compared to HROWM's ROE of -0.34%. Regarding short-term risk, IPXL is more volatile compared to HROWM. This indicates higher risk in terms of short-term price fluctuations for IPXL.Check HROWM's competition here

Impax Laboratories, Inc. (NASDAQ: IPXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPXL stands at 0. In comparison, CUVL has a market cap of 336.6M. Regarding current trading prices, IPXL is priced at $18.30 on the NASDAQ, while CUVL trades at $6.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPXL currently has a P/E ratio of -10.11, whereas CUVL's P/E ratio is N/A. In terms of profitability, IPXL's ROE is -1.16%, compared to CUVL's ROE of N/A. Regarding short-term risk, IPXL is less volatile compared to CUVL. This indicates lower risk in terms of short-term price fluctuations for IPXL.Check CUVL's competition here

Impax Laboratories, Inc. (NASDAQ: IPXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPXL stands at 0. In comparison, LFMD has a market cap of 172.2M. Regarding current trading prices, IPXL is priced at $18.30 on the NASDAQ, while LFMD trades at $3.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPXL currently has a P/E ratio of -10.11, whereas LFMD's P/E ratio is -7.12. In terms of profitability, IPXL's ROE is -1.16%, compared to LFMD's ROE of -1.79%. Regarding short-term risk, IPXL is more volatile compared to LFMD. This indicates higher risk in terms of short-term price fluctuations for IPXL.Check LFMD's competition here

Impax Laboratories, Inc. (NASDAQ: IPXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPXL stands at 0. In comparison, LFMDP has a market cap of 160M. Regarding current trading prices, IPXL is priced at $18.30 on the NASDAQ, while LFMDP trades at $23.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPXL currently has a P/E ratio of -10.11, whereas LFMDP's P/E ratio is -722.96. In terms of profitability, IPXL's ROE is -1.16%, compared to LFMDP's ROE of -1.79%. Regarding short-term risk, IPXL is more volatile compared to LFMDP. This indicates higher risk in terms of short-term price fluctuations for IPXL.Check LFMDP's competition here

Impax Laboratories, Inc. (NASDAQ: IPXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPXL stands at 0. In comparison, CIRC has a market cap of 65.1M. Regarding current trading prices, IPXL is priced at $18.30 on the NASDAQ, while CIRC trades at $0.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPXL currently has a P/E ratio of -10.11, whereas CIRC's P/E ratio is -1.64. In terms of profitability, IPXL's ROE is -1.16%, compared to CIRC's ROE of +0.00%. Regarding short-term risk, IPXL is less volatile compared to CIRC. This indicates lower risk in terms of short-term price fluctuations for IPXL.Check CIRC's competition here

Impax Laboratories, Inc. (NASDAQ: IPXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPXL stands at 0. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, IPXL is priced at $18.30 on the NASDAQ, while RAD trades at $0.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPXL currently has a P/E ratio of -10.11, whereas RAD's P/E ratio is -0.05. In terms of profitability, IPXL's ROE is -1.16%, compared to RAD's ROE of +2.76%. Regarding short-term risk, IPXL is less volatile compared to RAD. This indicates lower risk in terms of short-term price fluctuations for IPXL.Check RAD's competition here

Impax Laboratories, Inc. (NASDAQ: IPXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPXL stands at 0. In comparison, GLTO has a market cap of 34.5M. Regarding current trading prices, IPXL is priced at $18.30 on the NASDAQ, while GLTO trades at $21.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPXL currently has a P/E ratio of -10.11, whereas GLTO's P/E ratio is -1.78. In terms of profitability, IPXL's ROE is -1.16%, compared to GLTO's ROE of -1.22%. Regarding short-term risk, IPXL is less volatile compared to GLTO. This indicates lower risk in terms of short-term price fluctuations for IPXL.Check GLTO's competition here

Impax Laboratories, Inc. (NASDAQ: IPXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPXL stands at 0. In comparison, SCYX has a market cap of 33M. Regarding current trading prices, IPXL is priced at $18.30 on the NASDAQ, while SCYX trades at $5.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPXL currently has a P/E ratio of -10.11, whereas SCYX's P/E ratio is -1.53. In terms of profitability, IPXL's ROE is -1.16%, compared to SCYX's ROE of -0.57%. Regarding short-term risk, IPXL is more volatile compared to SCYX. This indicates higher risk in terms of short-term price fluctuations for IPXL.Check SCYX's competition here

Impax Laboratories, Inc. (NASDAQ: IPXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPXL stands at 0. In comparison, NSRX has a market cap of 29.8M. Regarding current trading prices, IPXL is priced at $18.30 on the NASDAQ, while NSRX trades at $3.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPXL currently has a P/E ratio of -10.11, whereas NSRX's P/E ratio is -4.80. In terms of profitability, IPXL's ROE is -1.16%, compared to NSRX's ROE of +0.00%. Regarding short-term risk, IPXL is less volatile compared to NSRX. This indicates lower risk in terms of short-term price fluctuations for IPXL.Check NSRX's competition here

Impax Laboratories, Inc. (NASDAQ: IPXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPXL stands at 0. In comparison, SDEV has a market cap of 28.2M. Regarding current trading prices, IPXL is priced at $18.30 on the NASDAQ, while SDEV trades at $1.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPXL currently has a P/E ratio of -10.11, whereas SDEV's P/E ratio is -0.18. In terms of profitability, IPXL's ROE is -1.16%, compared to SDEV's ROE of +7.90%. Regarding short-term risk, IPXL is more volatile compared to SDEV. This indicates higher risk in terms of short-term price fluctuations for IPXL.Check SDEV's competition here

Impax Laboratories, Inc. (NASDAQ: IPXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPXL stands at 0. In comparison, BFRI has a market cap of 16.3M. Regarding current trading prices, IPXL is priced at $18.30 on the NASDAQ, while BFRI trades at $1.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPXL currently has a P/E ratio of -10.11, whereas BFRI's P/E ratio is -1.19. In terms of profitability, IPXL's ROE is -1.16%, compared to BFRI's ROE of -4.77%. Regarding short-term risk, IPXL is more volatile compared to BFRI. This indicates higher risk in terms of short-term price fluctuations for IPXL.Check BFRI's competition here

Impax Laboratories, Inc. (NASDAQ: IPXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPXL stands at 0. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, IPXL is priced at $18.30 on the NASDAQ, while CJJD trades at $1.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPXL currently has a P/E ratio of -10.11, whereas CJJD's P/E ratio is -0.46. In terms of profitability, IPXL's ROE is -1.16%, compared to CJJD's ROE of -0.25%. Regarding short-term risk, IPXL is more volatile compared to CJJD. This indicates higher risk in terms of short-term price fluctuations for IPXL.Check CJJD's competition here

Impax Laboratories, Inc. (NASDAQ: IPXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPXL stands at 0. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, IPXL is priced at $18.30 on the NASDAQ, while SSY trades at $1.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPXL currently has a P/E ratio of -10.11, whereas SSY's P/E ratio is -2.86. In terms of profitability, IPXL's ROE is -1.16%, compared to SSY's ROE of -0.09%. Regarding short-term risk, IPXL is less volatile compared to SSY. This indicates lower risk in terms of short-term price fluctuations for IPXL.Check SSY's competition here

Impax Laboratories, Inc. (NASDAQ: IPXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPXL stands at 0. In comparison, POM has a market cap of 5.9M. Regarding current trading prices, IPXL is priced at $18.30 on the NASDAQ, while POM trades at $0.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPXL currently has a P/E ratio of -10.11, whereas POM's P/E ratio is -0.17. In terms of profitability, IPXL's ROE is -1.16%, compared to POM's ROE of +0.16%. Regarding short-term risk, IPXL is less volatile compared to POM. This indicates lower risk in terms of short-term price fluctuations for IPXL.Check POM's competition here

Impax Laboratories, Inc. (NASDAQ: IPXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPXL stands at 0. In comparison, PAVS has a market cap of 5.3M. Regarding current trading prices, IPXL is priced at $18.30 on the NASDAQ, while PAVS trades at $6.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPXL currently has a P/E ratio of -10.11, whereas PAVS's P/E ratio is -0.07. In terms of profitability, IPXL's ROE is -1.16%, compared to PAVS's ROE of -0.27%. Regarding short-term risk, IPXL is less volatile compared to PAVS. This indicates lower risk in terms of short-term price fluctuations for IPXL.Check PAVS's competition here

Impax Laboratories, Inc. (NASDAQ: IPXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPXL stands at 0. In comparison, HKPD has a market cap of 4.6M. Regarding current trading prices, IPXL is priced at $18.30 on the NASDAQ, while HKPD trades at $0.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPXL currently has a P/E ratio of -10.11, whereas HKPD's P/E ratio is -7.01. In terms of profitability, IPXL's ROE is -1.16%, compared to HKPD's ROE of -0.14%. Regarding short-term risk, IPXL is more volatile compared to HKPD. This indicates higher risk in terms of short-term price fluctuations for IPXL.Check HKPD's competition here

Impax Laboratories, Inc. (NASDAQ: IPXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPXL stands at 0. In comparison, AIXC has a market cap of 4.3M. Regarding current trading prices, IPXL is priced at $18.30 on the NASDAQ, while AIXC trades at $0.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPXL currently has a P/E ratio of -10.11, whereas AIXC's P/E ratio is -0.09. In terms of profitability, IPXL's ROE is -1.16%, compared to AIXC's ROE of -0.94%. Regarding short-term risk, IPXL is less volatile compared to AIXC. This indicates lower risk in terms of short-term price fluctuations for IPXL.Check AIXC's competition here

Impax Laboratories, Inc. (NASDAQ: IPXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPXL stands at 0. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, IPXL is priced at $18.30 on the NASDAQ, while MDVL trades at $1.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPXL currently has a P/E ratio of -10.11, whereas MDVL's P/E ratio is -0.05. In terms of profitability, IPXL's ROE is -1.16%, compared to MDVL's ROE of -2.39%. Regarding short-term risk, IPXL is less volatile compared to MDVL. This indicates lower risk in terms of short-term price fluctuations for IPXL.Check MDVL's competition here

Impax Laboratories, Inc. (NASDAQ: IPXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPXL stands at 0. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, IPXL is priced at $18.30 on the NASDAQ, while ATNFW trades at $0.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPXL currently has a P/E ratio of -10.11, whereas ATNFW's P/E ratio is N/A. In terms of profitability, IPXL's ROE is -1.16%, compared to ATNFW's ROE of -2.41%. Regarding short-term risk, IPXL is less volatile compared to ATNFW. This indicates lower risk in terms of short-term price fluctuations for IPXL.Check ATNFW's competition here

Impax Laboratories, Inc. (NASDAQ: IPXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPXL stands at 0. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, IPXL is priced at $18.30 on the NASDAQ, while BGMSP trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPXL currently has a P/E ratio of -10.11, whereas BGMSP's P/E ratio is -0.84. In terms of profitability, IPXL's ROE is -1.16%, compared to BGMSP's ROE of -0.51%. Regarding short-term risk, IPXL is more volatile compared to BGMSP. This indicates higher risk in terms of short-term price fluctuations for IPXL.Check BGMSP's competition here

Impax Laboratories, Inc. (NASDAQ: IPXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPXL stands at 0. In comparison, BGMS has a market cap of 2M. Regarding current trading prices, IPXL is priced at $18.30 on the NASDAQ, while BGMS trades at $0.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPXL currently has a P/E ratio of -10.11, whereas BGMS's P/E ratio is -0.26. In terms of profitability, IPXL's ROE is -1.16%, compared to BGMS's ROE of -0.51%. Regarding short-term risk, IPXL is more volatile compared to BGMS. This indicates higher risk in terms of short-term price fluctuations for IPXL.Check BGMS's competition here

Impax Laboratories, Inc. (NASDAQ: IPXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPXL stands at 0. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, IPXL is priced at $18.30 on the NASDAQ, while AZNH trades at $53.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPXL currently has a P/E ratio of -10.11, whereas AZNH's P/E ratio is 38.35. In terms of profitability, IPXL's ROE is -1.16%, compared to AZNH's ROE of +0.00%. Regarding short-term risk, IPXL is more volatile compared to AZNH. This indicates higher risk in terms of short-term price fluctuations for IPXL.Check AZNH's competition here

Impax Laboratories, Inc. (NASDAQ: IPXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPXL stands at 0. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, IPXL is priced at $18.30 on the NASDAQ, while LFLYW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPXL currently has a P/E ratio of -10.11, whereas LFLYW's P/E ratio is -0.00. In terms of profitability, IPXL's ROE is -1.16%, compared to LFLYW's ROE of +0.42%. Regarding short-term risk, IPXL is more volatile compared to LFLYW. This indicates higher risk in terms of short-term price fluctuations for IPXL.Check LFLYW's competition here

Impax Laboratories, Inc. (NASDAQ: IPXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPXL stands at 0. In comparison, SBFMW has a market cap of 175.2K. Regarding current trading prices, IPXL is priced at $18.30 on the NASDAQ, while SBFMW trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPXL currently has a P/E ratio of -10.11, whereas SBFMW's P/E ratio is N/A. In terms of profitability, IPXL's ROE is -1.16%, compared to SBFMW's ROE of -0.26%. Regarding short-term risk, IPXL is less volatile compared to SBFMW. This indicates lower risk in terms of short-term price fluctuations for IPXL.Check SBFMW's competition here

Impax Laboratories, Inc. (NASDAQ: IPXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPXL stands at 0. In comparison, ESRX has a market cap of 0. Regarding current trading prices, IPXL is priced at $18.30 on the NASDAQ, while ESRX trades at $92.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPXL currently has a P/E ratio of -10.11, whereas ESRX's P/E ratio is 10.69. In terms of profitability, IPXL's ROE is -1.16%, compared to ESRX's ROE of +0.26%. Regarding short-term risk, IPXL is more volatile compared to ESRX. This indicates higher risk in terms of short-term price fluctuations for IPXL.Check ESRX's competition here

Impax Laboratories, Inc. (NASDAQ: IPXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPXL stands at 0. In comparison, CPD has a market cap of 0. Regarding current trading prices, IPXL is priced at $18.30 on the NASDAQ, while CPD trades at $5.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPXL currently has a P/E ratio of -10.11, whereas CPD's P/E ratio is N/A. In terms of profitability, IPXL's ROE is -1.16%, compared to CPD's ROE of N/A. Regarding short-term risk, IPXL is more volatile compared to CPD. This indicates higher risk in terms of short-term price fluctuations for IPXL.Check CPD's competition here

Impax Laboratories, Inc. (NASDAQ: IPXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPXL stands at 0. In comparison, OREX has a market cap of 0. Regarding current trading prices, IPXL is priced at $18.30 on the NASDAQ, while OREX trades at $0.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPXL currently has a P/E ratio of -10.11, whereas OREX's P/E ratio is -0.14. In terms of profitability, IPXL's ROE is -1.16%, compared to OREX's ROE of -0.54%. Regarding short-term risk, IPXL is less volatile compared to OREX. This indicates lower risk in terms of short-term price fluctuations for IPXL.Check OREX's competition here

Impax Laboratories, Inc. (NASDAQ: IPXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPXL stands at 0. In comparison, POZN has a market cap of 0. Regarding current trading prices, IPXL is priced at $18.30 on the NASDAQ, while POZN trades at $5.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPXL currently has a P/E ratio of -10.11, whereas POZN's P/E ratio is N/A. In terms of profitability, IPXL's ROE is -1.16%, compared to POZN's ROE of +0.61%. Regarding short-term risk, IPXL is less volatile compared to POZN. This indicates lower risk in terms of short-term price fluctuations for IPXL.Check POZN's competition here

Impax Laboratories, Inc. (NASDAQ: IPXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IPXL stands at 0. In comparison, SHPG has a market cap of 0. Regarding current trading prices, IPXL is priced at $18.30 on the NASDAQ, while SHPG trades at $179.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IPXL currently has a P/E ratio of -10.11, whereas SHPG's P/E ratio is 11.35. In terms of profitability, IPXL's ROE is -1.16%, compared to SHPG's ROE of +0.13%. Regarding short-term risk, IPXL is more volatile compared to SHPG. This indicates higher risk in terms of short-term price fluctuations for IPXL.Check SHPG's competition here